Skip to main content

Table 4 Baseline moderate-severe symptoms or functional problems and changes at 12 months for the full cohort at both time points

From: Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Health-related quality of life domains

Symptoms and functional problems at baseline, n (%)

(N = 90)

Changes from baseline to 12 months, n (%)

(N = 50)

Mild or no symptoms

Moderate

Severe

No change

Deterioration

Improvement

EORTC-QLQ-C30

Global health status

30 (33)

41 (46)

19 (21)

30 (59)

7 (14)

13 (27)

Physical functioning

60 (70)

20 (22)

7 (8)

37 (74)

5 (10)

8 (16)

Role functioning

36 (40)

31 (34)

23 (26)

28 (56)

8 (16)

14 (28)

Emotional functioning

64 (71)

23 (26)

3 (3)

34 (68)

8 (16)

8 (16)

Cognitive functioning

66 (74)

20 (22)

4 (4)

36 (72)

8 (16)

6 (12)

Social functioning

57 (63)

25 (28)

8 (9)

36 (72)

3 (6)

11 (22)

Fatigue

30 (34)

40 (44)

20 (22)

28 (56)

9 (18)

13 (26)

Nausea and vomiting

79 (88)

8 (9)

3 (3)

44 (88)

2 (4)

4 (8)

Pain

50 (56)

28 (31)

12 (13)

35 (70)

4 (8)

11 (22)

Dyspnea

52 (57)

30 (34)

8 (9)

38 (76)

5 (10)

7 (14)

Insomnia

45 (50)

26 (29)

19 (21)

29 (58)

9 (18)

12 (24)

Appetite loss

55 (62)

22 (24)

13 (14)

27 (54)

8 (16)

15 (30)

Constipation

71 (79)

12 (13)

7 (8)

39 (78)

6 (12)

5 (10)

Diarrhea

60 (67)

19 (21)

11 (12)

33 (66)

9 (18)

8 (16)

Financial difficulties

80 (89)

8 (9)

2 (2)

43 (86)

3 (6)

4 (8)

HADS

Anxiety

89 (99)

1 (1)

NA

44 (87)

5 (11)

1 (2)

Depression

89 (99)

1 (1)

NA

48 (96)

1 (2)

1 (2)

  1. N, number of patients; NA, not applicable; SD, standard deviation; EORTC, European Organization for Research and Treatment of Cancer; HADS, Hospital Anxiety and Depression Scale
  2. The three highest estimates for moderate and severe symptoms/functional problems and improvement/deterioration are marked in bold